Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on BEAM stock, giving a Buy rating today.

Patrick Trucchio has given his Buy rating due to a combination of factors tied mainly to BEAM-302’s clinical and commercial potential in alpha-1 antitrypsin deficiency. He highlights that the latest Phase 1/2 results show a single 60 mg dose can lift AAT levels well above the protective threshold, sharply reduce the harmful Z-AAT variant, and largely replace it with the corrected M-AAT, supporting a clear path to a pivotal trial under an FDA-aligned accelerated approval strategy.

He also notes that BEAM-302’s profile appears differentiated, with durable responses, near-maximal editing at the selected dose, and encouraging performance even in patients with liver involvement, all while maintaining a generally favorable safety profile in single-dose use. Combined with his forecast that BEAM-302 could ultimately deliver multibillion-dollar peak sales and his risk-adjusted valuation that supports an $80 target price, these elements underpin his positive view on Beam’s risk‑reward setup despite acknowledged development, competitive, and financing risks.

Trucchio covers the Healthcare sector, focusing on stocks such as Gossamer Bio, Atai Beckley N.V., and Alnylam Pharma. According to TipRanks, Trucchio has an average return of 23.9% and a 46.03% success rate on recommended stocks.